托法替布治疗类风湿关节炎长达9.5年的长期安全性:综合整合分析
结果显示严重不良事件发生率9.0/100患者年,严重感染2.5/100患者年,带状疱疹3.6/100患者年,各项发生率与既往报告一致且随时间保持稳定。
要点
- 严重不良事件发生率9.0/100患者年,严重感染2.5/100患者年。
- 带状疱疹发生率3.6/100患者年,机会性感染(除结核)0.4/100患者年。
- 恶性肿瘤(除NMSC)0.8/100患者年,NMSC 0.6/100患者年,淋巴瘤0.1/100患者年。
核心结论
- 托法替布治疗类风湿关节炎的长期安全性数据与既往报告一致,各项不良事件发生率随时间保持稳定。
研究设计与样本
- 整合分析托法替布治疗类风湿关节炎的I、II、III、IIIb/IV期及长期扩展研究数据,纳入7061例接受至少1次托法替布剂量的患者。
主要发现
- 严重不良事件发生率9.0/100患者年(95%CI 8.6-9.4),严重感染2.5/100患者年(95%CI 2.3-2.7)。
- 带状疱疹(全部)3.6/100患者年(95%CI 3.4-3.9),机会性感染(除结核)0.4/100患者年(95%CI 0.3-0.5),结核0.2/100患者年(95%CI 0.1-0.2)。
- 恶性肿瘤(除NMSC)0.8/100患者年(95%CI 0.7-0.9),NMSC 0.6/100患者年(95%CI 0.5-0.7),淋巴瘤0.1/100患者年(95%CI 0.0-0.1)。
- 胃肠道穿孔0.1/100患者年(95%CI 0.1-0.2),深静脉血栓0.2/100患者年(95%CI 0.1-0.2),肺栓塞0.1/100患者年(95%CI 0.1-0.2)。
- 静脉血栓栓塞0.3/100患者年(95%CI 0.2-0.3),动脉血栓栓塞0.4/100患者年(95%CI 0.3-0.5),主要心血管不良事件0.4/100患者年(95%CI 0.3-0.5),死亡率0.3/100患者年(95%CI 0.2-0.3)。
关键数值与推荐
- 各项不良事件发生率在6个月间隔至超过78个月期间基本保持一致。
临床怎么用
- 临床使用托法替布治疗类风湿关节炎时,可参考上述长期安全性数据监测严重感染、带状疱疹、恶性肿瘤、血栓栓塞及心血管事件等风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. METHODS: Data were pooled for patients with RA who received ≥1 tofacitinib dose. Incidence rates (IRs; patients with events/100 patient-years [PY]; 95% CIs) of first-time occurrences were obtained for adverse events (AEs) of interest. RESULTS: 7061 patients received tofacitinib (total exposure: 22 875 PY; median [range] exposure: 3.1 [0 to 9.6] years). IRs (95% CI) for serious AEs, serious infections, herpes zoster (all), opportunistic infections (excluding tuberculosis [TB]) and TB were 9.0 (8.6 to 9.4), 2.5 (2.3 to 2.7), 3.6 (3.4 to 3.9), 0.4 (0.3 to 0.5) and 0.2 (0.1 to 0.2), respectively. IRs (95% CI) for malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC and lymphomas were 0.8 (0.7 to 0.9), 0.6 (0.5 to 0.7) and 0.1 (0.0 to 0.1), respectively. IRs (95% CI) for gastrointestinal perforations, deep vein thrombosis, pulmonary embolism, venous thromboembolism, arterial thromboembolism and major adverse cardiovascular events were 0.1 (0.1 to 0.2), 0.2 (0.1 to 0.2), 0.1 (0.1 to 0.2), 0.3 (0.2 to 0.3), 0.4 (0.3 to 0.5) and 0.4 (0.3 to 0.5), respectively. IR (95% CI) for mortality was 0.3 (0.2 to 0.3). IRs generally remained consistent across 6-month intervals to >78 months. CONCLUSION: This represents the largest clinical dataset for a JAK inhibitor in RA to date. IRs remained consistent with previous reports from the tofacitinib RA clinical development programme, and stable over time. TRIAL REGISTRATION NUMBERS: NCT01262118; NCT01484561; NCT00147498; NCT00413660; NCT00550446; NCT00603512; NCT00687193; NCT01164579; NCT00976599; NCT01059864; NCT01359150; NCT02147587; NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT01039688; NCT02187055; NCT00413699; NCT00661661.For summary of phase I, phase II, phase III, phase IIIb/IV and LTE studies included in the integrated safety analysis, see online supplemental table 1.
引用
- Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020. PMID: 33127856. doi:10.1136/rmdopen-2020-001395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。